BDBM107709 US11426393, Compound Table XV.15::US8598210, Table XV, 15::US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxypyridine-2-carbonyl]amino}-acetic acid::US9598370, Example 00140::USRE47437, Example {[5-(4-Isopropoxyphenyl)-3-hydroxypyridine-2-carbonyl]amino}-aceticacid

SMILES CC(C)Oc1ccc(cc1)-c1cnc(C(=O)NCC(O)=O)c(O)c1

InChI Key InChIKey=XAQQOGZYOJAKKO-UHFFFAOYSA-N

Data  5 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 107709   

TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataIC50:  1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataIC50:  1.60E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataIC50:  1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataIC50:  1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataIC50:  1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US11426393, Compound Table XV.15 | US8598210, Tabl...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In DepthDetails US Patent